Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Rating of “Hold” by Brokerages

Pacira BioSciences, Inc. (NASDAQ:PCRX) has received an average rating of “Hold” from the ten analysts that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $24.50.

A number of analysts have weighed in on PCRX shares. Jefferies Financial Group increased their price objective on Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. HC Wainwright restated a “buy” rating and set a $39.00 price target on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Needham & Company LLC boosted their price objective on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Royal Bank of Canada restated a “sector perform” rating and set a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Barclays lowered their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th.

Institutional Trading of Pacira BioSciences

Institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC lifted its position in shares of Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after acquiring an additional 2,749 shares during the period. CWM LLC boosted its position in Pacira BioSciences by 713.6% during the third quarter. CWM LLC now owns 6,517 shares of the company’s stock worth $98,000 after purchasing an additional 5,716 shares in the last quarter. Virtus Investment Advisers Inc. acquired a new stake in Pacira BioSciences in the third quarter valued at $98,000. China Universal Asset Management Co. Ltd. increased its position in shares of Pacira BioSciences by 62.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock valued at $134,000 after buying an additional 3,404 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Pacira BioSciences during the 2nd quarter worth $140,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

Shares of PCRX opened at $22.36 on Friday. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -11.01 and a beta of 0.76. Pacira BioSciences has a fifty-two week low of $11.16 and a fifty-two week high of $34.01. The firm has a 50-day simple moving average of $18.71 and a 200-day simple moving average of $17.47. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.